The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The effect of estrogen replacement on early Parkinson’s disease
Abstract
OBJECTIVE: To determine the effect of estrogen in postmenopausal women with early PD. BACKGROUND: The role of estrogen in PD is highly disputed, with some studies suggesting a prodopaminergic effect and others suggesting an antidopaminergic effect. Owing to controversy and the small sample sizes of prior studies, further investigation is warranted. METHODS: A retrospective chart review was carried out from a computerized database of patients at Columbia-Presbyterian, including only women who had symptoms of presumed PD for less than 5 years and who had not yet been on L-dopa at their first visit. Multiple regression was performed to assess the effects of estrogen on disease, measured by total Unified Parkinson's Disease Rating Scale (UPDRS) score, as a function of symptom duration, age at onset, education, smoking, dopamine agonist, and deprenyl use. RESULTS: Of the women who were not on L-dopa and had PD for less than 5 years at their first visit, 34 were found to have received estrogen at some time and 104 had never received estrogen. Excluding the women who had taken dopamine agonists, analysis yielded a multiple regression coefficient of 0.52 (p < 0.001). Estrogen use was negatively correlated with UPDRS score; age at onset and symptom duration were positively correlated (p < 0.05). CONCLUSIONS: We found a positive association between estrogen use and lower symptom severity in women with early PD not yet taking L-dopa. These results indicate that estrogen therapy should not be avoided and may be beneficial in early PD, at least prior to the initiation of L-dopa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Gerfen, C. R. (1984) · Nature · doi:10.1038/311461a0 · Cited by 837
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
Metman, L. V., Del Dotto, P., van den Munckhof, P., Fang, J., Mouradian, M. M., & Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.50.5.1323 · Cited by 514
Mayeux, R. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530290076015 · Cited by 383
Lieberman, A., Dziatolowski, M., Kupersmith, M., Serby, M., Goodgold, A., Korein, J., & Goldstein, M. (1979) · Annals of Neurology · doi:10.1002/ana.410060409 · Cited by 370
Effects of estrogen on the basal ganglia
Van Hartesveldt, C., & Joyce, J. N. (1986) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(86)90029-1 · Cited by 238
Increased Dopamine Receptor Sensitivity After Estrogen Treatment Using the Rat Rotation Model
Hruska, R. E., & Silbergeld, E. K. (1980) · Science · doi:10.1126/science.7189902 · Cited by 224
ŒSTROGENS AND EXTRAPYRAMIDAL SYSTEM
Bedard, P., Langelier, P., & Villeneuve, A. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90429-9 · Cited by 179
Gender differences in Parkinson's disease.
Lyons, K. E., Hubble, J. P., Tröster, A. I., Pahwa, R., & Koller, W. C. (1998) · PubMed · Cited by 177
The influence of estrogen on nigrostriatal dopamine activity
Becker, J. B., & Beer, M. E. (1986) · Behavioural Brain Research · doi:10.1016/0166-4328(86)90044-6 · Cited by 175
Postmenopausal estrogen use and Parkinson's disease with and without dementia
Marder, K. S., Tang, M. X., Alfaro, B., Mejía, H., Cote, L. J., Jacobs, D. M., Stern, Y., Sano, M. C., & Mayeux, R. P. (1998) · Neurology · doi:10.1212/wnl.50.4.1141 · Cited by 153
An examination of male‐female differences in progression and mortality of Parkinson's disease
Diamond, S. G., Markham, C. H., Hoehn, M. M. M., MCDOWELL, F. H., & Muenter, M. D. (1990) · Neurology · doi:10.1212/wnl.40.5.763 · Cited by 131
Menstrual‐related fluctuations in Parkinson's disease
Quinn, N. P., & MARSDEN, C. D. (1986) · Movement Disorders · doi:10.1002/mds.870010112 · Cited by 126
How accurately can Parkinson's disease be diagnosed?
Wc, K. (1992) · PubMed · Cited by 114
Estrogen treatment of dyskinetic disorders
Koller, W. C., Barr, A., & Biary, N. M. (1982) · Neurology · doi:10.1212/wnl.32.5.547 · Cited by 97
Chiodo, L. A., & Caggiula, A. R. (1983) · Neuropharmacology · doi:10.1016/0028-3908(83)90150-8 · Cited by 71
Dluzen, D. E. (1996) · Brain Research · doi:10.1016/0006-8993(95)01566-3 · Cited by 70
Estrogen treatment increases the density of D1 dopamine receptors in the rat striatum
Hruska, R. E., & Nowak, M. W. (1988) · Brain Research · doi:10.1016/0006-8993(88)91523-5 · Cited by 64
Menstrual-related changes in motoric function in women with Parkinson’s disease
Kompoliti, K., Comella, C. L., Jaglin, J. A., Leurgans, S. E., Raman, R., & Goetz, C. G. (2000) · Neurology · doi:10.1212/wnl.55.10.1572 · Cited by 51
Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period
Mizuta, E., Yamasaki, S., Nakatake, M., & Kuno, S. (1993) · Neurology · doi:10.1212/wnl.43.5.1048 · Cited by 36
Neurology of Sex Steroids and Oral Contraceptives
Schipper, H. M. (1986) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30945-9 · Cited by 34
Hormones and Parkinson's disease
Giladi, N., & Honigman, S. (1995) · Neurology · doi:10.1212/wnl.45.5.1028-a · Cited by 27
BENEFITS AND RISKS OF HORMONE/ESTROGEN REPLACEMENT
Thomas, D. J. (1996) · Nursing Clinics of North America · doi:10.1016/s0029-6465(22)00190-6 · Cited by 5
Cited by
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Gillies, G. E., & McArthur, S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002071 · Cited by 733
“…(Liu and Dluzen, 2007), a significant number of studies also conclude that the symptoms and risk of developing PD are reduced by estrogen treatment (Saunders-Pullman et al., 1999; Tsang et al., 2000; Benedetti et al., 2001; Shulman and Bhat, 2006) and prolonged natural exposure to endogenous…”
BackgroundNeuroprotective effects of estrogens: potential mechanisms of action
Green, P. S., & Simpkins, J. W. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00017-4 · Cited by 523
Sex differences in Parkinson’s disease
Gillies, G. E., Pienaar, I. S., Vohra, S., & Qamhawi, Z. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.02.002 · Cited by 489
Reflections on the Discovery and Significance of Estrogen Receptor β
Koehler, K. F., Helguero, L. A., Haldosén, L.-A., Warner, M., & Gustafsson, J.-A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0027 · Cited by 360
Metadata
- Authors
- Saunders-Pullman, R., Gordon-Elliott, J., Parides, M., Fahn, S., Saunders, H. R., & Bressman, S.
- Venue
- Neurology
- Published
- 1999-04
- Volume
- 52
- Issue
- 7
- Pages
- 1417-1417
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1999649731
- Cited by
- 270
- References
- 23
- FWCI
- 12.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.